论文部分内容阅读
目的研究前列腺癌经去势治疗后出现去势抵抗与全身炎症指标相关性。方法回顾性分析199例接受内分泌治疗的前列腺癌患者的临床资料。根据其出现去势抵抗时间将其分为<1年、1~3年、3~5年复发和5年内未复发四组。分析各组患者穿刺诊断前总前列腺特异性抗原(tPSA)、C反应蛋白(CRP)、白蛋白(Alb)、改良格拉斯哥预后评分(mGPS)、临床分期、Glasgow评分以及是否存在骨转移与患者出现去势抵抗时间的相关性。结果各组患者的临床分期、Gleason评分、tPSA、CRP、Alb及mGPS均有统计学差异(P<0.05)。患者术前mGPS、CRP及Gleason评分越高,在1年和3年内发生去势抵抗的风险越高。多因素Logistic回归分析发现,CRP>10mg/L、Gleason评分≥8分和mGPS≥1分为前列腺癌出现去势抵抗进展时间的独立危险因素(P<0.05)。结论全身炎症指标可能可作为预测前列腺癌出现去势抵抗进展时间的独立危险因素。
Objective To study the relationship between castration resistance and systemic inflammation after castration treatment of prostate cancer. Methods The clinical data of 199 patients with endocrine-treated prostate cancer were retrospectively analyzed. According to their appearance of castration resistance time is divided into <1 year, 1 to 3 years, 3-5 years of recurrence and no relapse within 5 years four groups. The total prostate specific antigen (tPSA), C-reactive protein (CRP), albumin (Alb), modified Glasgow prognostic score (mGPS), clinical stage, Glasgow score and the presence or absence of bone metastases Correlation of castration resistance time. Results The clinical stage, Gleason score, tPSA, CRP, Alb and mGPS in each group were significantly different (P <0.05). Patients with preoperative mGPS, CRP and Gleason score higher, in 1 year and 3 years, the higher the risk of castration resistance. Multivariate logistic regression analysis showed that CRP> 10mg / L, Gleason score≥8 points and mGPS≥1 were independent risk factors for the progression of castration resistance in prostate cancer (P <0.05). Conclusion The index of systemic inflammation may be an independent risk factor for predicting the progress of castration resistance in prostate cancer.